生产企业：Teva Pharmaceuticals
Fremanezumab is a humanized monoclonal antibody directed against human calcitonin-gene related peptide to prevent migraines.
Fremanezumab is a humanized monoclonal antibody directed against human calcitonin-gene related peptide to prevent migraines.
Studies dating back to 1985 have demonstrated that CGRP levels increase during acute migraine attacks in migraine-suffering patients but normalize after administration of antimigraine therapy such as sumatriptan. Moreover, research has shown that intravenous administration of CGRP can induce migraine-like attacks in migraine-suffering patients. For these reasons, and despite the fact that their role in migraine headaches has not been entirely elucidated, CGRP and its receptors have become desirable targets for antimigraine therapies. Fremanezumab is a humanized monoclonal antibody directed against endogenous CGRP - it interferes with the activity of CGRP, preventing its downstream effects and ultimately mitigating the development of migraine headaches.
Fremanezumab is indicated for the preventative treatment of migraine in adults.
共 1 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
